

Ensuring Quality Hand Sanitizer Production During COVID-19

For Healthcare Professionals in the United States



Final Agenda

All times are in Eastern Daylight Time (EST) – Washington, DC time zone

- 9:00 a.m. – 9:05 a.m. **Welcome**
- 9:05 a.m. – 9:10 a.m. **Opening Remarks**
Speaker: Ronald T. Piervincenzi, Ph.D., Chief Executive Officer | USP
- Formal welcome highlighting why USP created a coordinated global response for safeguarding the global supply chain of alcohol-based hand sanitizers during COVID-19.
- 9:10 a.m. – 9:15 a.m. **Why Quality Alcohol-based Hand Sanitizer Matters**
Speaker: Nurisha Wade, Vice President, Healthcare Quality & Safety | USP
- Introduction to why it's critical to ensure quality production and the safe use of alcohol-based hand sanitizers (including its ingredients such as alcohol) during COVID-19 and beyond.
- 9:15 a.m. – 10:00 a.m. **Ensuring the Public's Trust in Using Alcohol-based Hand Sanitizer: Regulatory Overview**
Speaker: Theresa M. Michele, M.D., Director of the Office of Nonprescription Drugs (ONPD) in the Office of New Drugs, Center of Drug Evaluation and Research (CDER) | U.S. FDA
- Leading experts from the US FDA sharing regulatory and public health strategies to help ensure consumers' trust in alcohol-based hand sanitizer from compounding to safe use.
- 10:00 a.m. – 10:45 a.m. **Current State of Alcohol-based Hand Sanitizer: A Regional Perspective**
Ensuring the Public's Trust in Using Alcohol-based Hand Sanitizer: Regulatory Overview
Speaker: Francis Godwin, MBA, Office Director, Office of Manufacturing Quality | U.S. FDA
- Leading experts from the U.S. FDA share regulatory and public health strategies on how to increase consumers' trust in alcohol-based hand sanitizers from formulation to safe use.
- 10:45 a.m. – 11:00 a.m. **Break**
- 11:00 a.m. – 11:45 a.m. **Formulating Quality Alcohol-based Hand Sanitizer**
Speakers: Brenda Jensen, Compounding Expert Committee Member, and Brian Serumaga, Ph.D., Senior Manager-Personalized Medicines, Scientific Liaison | USP
- USP experts discuss standards and mitigation strategies to ensure quality compounding of alcohol-based hand sanitizer, including adequate levels of alcohol, and prevent serious hazards, such as methanol contamination.

Ensuring Quality Hand Sanitizer Production During COVID-19

For Healthcare Professionals in the United States



11:45 a.m. – 12:20 p.m.

Labeling, Packaging, Storage, & Distribution: Ensuring Quality During Hand Sanitizer's Journey

Speakers: Desmond G. Hunt, Ph.D., Principal Scientific Liaison, Science-General Chapters and Misti Spann, Pharm.D., Scientific Liaison, Science, Healthcare Quality & Safety | USP

USP experts discuss standards and mitigation strategies for the labeling, packaging, storage, transportation, and distribution of alcohol-based hand sanitizer.

12:20 a.m. – 1:00 p.m.

Lunch Break

1:00 p.m. – 1:35 p.m.

The Dos and Don'ts for Compounding Alcohol-based Hand Sanitizer Safely

Speaker: Tracy Acosta, Compounding Pharmacist | Preston Road Pharmacy

Compounder's perspective for the safe formulation, labeling, distribution, and storage of alcohol-based hand sanitizer

1:35 p.m. – 1:45 p.m.

Break

1:45 p.m. – 2:30 p.m.

Why it Matters: An Impact Perspective

Speaker: Daniel Brooks, M.D., Medical Director | Banner Poison & Drug Information Center

A clinical perspective on the impact of poor-quality alcohol-based hand sanitizers, methanol poisoning, and other dangers.

2:30 p.m. – 3:30 p.m.

Panel Discussion (LIVE)

A moderated discussion on the global dilemma of bringing new alcohol-based hand sanitizers to market while ensuring public understanding of proper, safe alcohol-based hand sanitizer use.

Panel Facilitator: Nurisha Wade, Vice President, Healthcare Quality & Safety | USP

Panelists:

- Tracy Acosta, Pharm.D., Compounding Pharmacist | Preston Road Pharmacy
- Frances Gail Bormel, R.PH., J.D., Acting Director for the Office of Compounding Quality and Compliance in (CDER) Office of Compliance | U.S. FDA
- Daniel Brooks, M.D., Medical Director | Banner Poison & Drug Information Center
- Theresa M. Michele, M.D., Director, Center for Drug Evaluation and Research's Division of Nonprescription Drug Products | U.S. FDA
- Brian Serumaga, Ph.D., Senior Manager-Personalized Medicines, Scientific Liaison | USP
- Misti Spann, Pharm.D., Scientific Liaison, Science, Healthcare Quality & Safety | USP

3:30 p.m.

Adjourn